Bio-Modeling Systems: The Mechanisms-Based Mecidicine Company
  • 2018: PRESS-RELEASE: Paris October 10, 2108: Bio-Modeling Systems, with its operational CADI™ Discovery platform, is the Integrative Biology partner of GEMMA (autism & microbiota) project selected for €14.2M H2020 funding by the European Commission to identify potential targets for the personalized treatment and prevention of Autism Spectrum Disorderss

  • 2018: PRESS-RELEASE: Paris 10 Octobre 2108: Bio-Modeling Systems, avec sa plateforme opérationnelle CADI™ Discovery est le partenaire « Biologie Intégrative » du  programme GEMMA (autisme & microbiote) sélectionné par la Commission européenne pour un financement H2020 de 14,2 millions d'euros afin d'identifier des cibles potentielles pour le traitement personnalisé et la prévention des troubles du spectre autistique

  • 2018: ANNOUNCEMENT: Paris September 4, 2018: How CADI Discovery, invented in 2004,  successfully addressed the "Garbage in Garbage out" Law of every Data Processing explained in Current Opinion in Pharmacology:  How scientific literature analysis yields innovative therapeutic hypothesis through integrative iterations.
     
  • 2018: PRESS-RELEASE: Paris  July17, 2018: World's first: The French Chronic Fatigue Syndrome Association decides to clinically evaluate the ME/CFS pathogenesis model produced by Bio-Modeling System.s

  • 2018: ANNOUNCEMENT: Paris June 19-20, 2018: BMSystems invited to the Microbiotes conference organized by Adebiotech to present its microbiota vision and CADI Discovery programs. 

  • 2018: ANNOUNCEMENT: Paris June 14, 2018: BMSystems invited to the Connected Health Conference organized by ANRT to present its Real life data strategy with its "patients & HCP digital pathways" partner Bolero.

  • 2018: ANNOUNCEMENT: Paris March 13-14, 2018: BMSystems invited to the Epigentic conference organised by Adebiotech to present its CADI Discovery program EPIGEN-DIAB with the Centrer of excelllence in Epigenetic in India.
Bio-Modeling Systems: The Mechanisms-Based Mecidicine Companys

Company

BMSystems' Group Profile

  • Independent Private Company incorporated in 2004, profitable since 2006.
  • 100% owned by its founders (no search for external investors for BMSystems company, open for its spin-offs).
  • The first Mechanisms-Based Medicine company that discovers novel diagnostic, therapeutic & prevention solutions.
  • A clear “Biology” driven company that intensively uses I.T. resources. Inventor and exclusive owner of all its technologies.
  • 24 vFTE* of which 9 vFTE scientists/professionals focused on CADI**™ research.
  • Long term strategic R&D and business collaborations with more than 100 partners’ professionals working on BMSystems’ related R&D programs.
  • Original dual business model that generates revenues through contractual R&D programs & patented novel therapeutic & prevention solutions through collaborative R&D programs with its partners.
  • Company strictly focus on Discovery, the validation phases and the patented discoveries developments are implemented outside the company with selected partners.
  • The largest IT life sciences and healthcare business offer with its strategic IT partner, Persistent Systems (Leading Indian IT company 7000 people, 250 M$, 85% of business in the USA).
  • Member of BiO (USA), MEDICEN (Health, IAR (Industrial biotech) clusters.
  • Member in France of Leem Biotech, Adebiotech, Medef, Centrale-Santé Think Tanks.
  • Founders, member of international organizations (HUGO, CHI, etc…).
  • A responsible Innnovation© company

 BMSystems' Science at a glance

  • Understanding the causal mechanisms of a disease is the first objective. Finding the most adapted biomarkers and solutions are the necessary consequences of the first objective.
  • BMSystems invented CADI™ Discovery in 2004, the first operational "Mechanisms-based Medicine" platform, dedicated to the discovery of cost-effective new diagnostic, therapeutic and prevention solutions for medicine, cosmetics, etc, ...
  • BMSystems' team builds heuristic non-mathematical in-silico models to generate novel disruptive concepts from scientific, medical & health data.
  • CADI™ Discovery and the competition download the document
  • CADI™ Discovery addresses both efficacy and safety issues, the main culprits for the unacceptable R&D attrition rate.
  • BMSystems already generated a significant pipeline of internal Research programs.
  • CADI™ patented novel therapies, already contributed to the creation of two funded Pharma SMEs at clinical stage.:

 BMSystems' dual business model:

  • BMSystems separates its CADI™ research (internal) from the outputs developments (external).
  • BMsystems does not sell its technologies nor give access to them.
  • BMSystems sells the outputs of its research programs to its clients through contractual research programs (options: Access, fees, success fees, Discovery fees).
  • BMSystems shares the outputs of its research programs to its partners through collaborative research programs (each partner finances its costs, shares IP, defines together the development options).
  • The contractual and collaborative businesses are limited to 50% each to secure long run business.
  • BMSystems has repeatedly proven to create business value from its unique new research paradigm.
  • A responsible Innnovation© process

*vFTE (varaible Full Time Equivalent)

Bio-Modeling Systems: a leading Integrative Heuristic Systems Biology / Predictive Integrative Biology Mechanisms-Based Medicine company that delivers